Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2008
11/20/2008US20080287364 Bitter Taste Receptors
11/20/2008US20080287359 Cadherin-11-mediated modulation of hair growth
11/20/2008US20080287357 Conjugate Comprising P21 Protein for the Treatment of Cancer
11/20/2008US20080287351 Nfkb Transcriptional Activity Inhibitory Agent and Anti-Inflammatory Agent and a Steroid Action Enhancing Agent
11/20/2008US20080287349 Fibroblast growth factor 20 and methods of use thereof
11/20/2008US20080287348 Soluble Hybrid Prion Proteins And Their Use In The Diagnosis, Prevention And Treatment Of Transmissible Spongiform Encephalopathies
11/20/2008US20080287344 Use of Amino Acids for Making Medicines for Treating Insulin Resistance
11/20/2008US20080287300 Co-precipitated carrageenan/xanthan gum compositions and processes for their preparation
11/20/2008US20080286847 Inhibiting multimeric porphobilinogen synthase; for use as drug, toothpaste, soap, disinfectant, anti-biofilm and herbicide
11/20/2008US20080286813 Antibody specific for mutant presenilin 1 and method of use thereof
11/20/2008US20080286810 Use of Inhibtors of Glutaminyl Cyclases for Treatment and Prevention of Disease
11/20/2008US20080286806 Ligand for G-protein coupled receptor GPR43 and uses thereof
11/20/2008US20080286789 Genomic polymorphism for predicting therapeutic response
11/20/2008US20080286781 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
11/20/2008US20080286390 Skin care composition
11/20/2008US20080286386 Enzyme inhibitors; gene expression inhibition
11/20/2008US20080286381 biodrug comprising a nucleic acid sequence of nucleic acid; anticarcinogenic agents or antitumor agents; including cisplatin and carboplatin; effective chemotherapeutic agents in efficiency, being less invasive or toxic, and increased rate of recovery
11/20/2008US20080286377 disodium pamidronate or etidronate antiresorptive agent having a particle-size distribution same or less than that of polymethyl methacrylate bone-cement to provide even distribution of anti-resorptive particles throughout a polymerized bone-cement matrix after polymerization; a bone cement monomer
11/20/2008US20080286373 ziprasidone, ziprasidone hcl; mono, di or triglycerides of C12-24 fatty acids, mono, or diesters of c12-c24 fatty acid and polyoxyethylene glycol, vitamin E tocopherol-succinic acid-polyethyleneglycol; sodium lauryl sulfate as anionic surfactant; hydroxyalkylalkyl cellulose; improved bioavailability;
11/20/2008US20080286372 Therapeutic compositions for targeted vessel delivery
11/20/2008US20080286368 administered sublingually in combination with a bio/mucoadhesion promoting compound (e.g. hydroxypropyl cellulose) in a manner giving rise to pharmacologically effective plasma levels of zolpidam, morphine, sufentanyl etc.within a short time after administration to treat pain, insomnia, diabetes etc
11/20/2008US20080286366 mammal blood platelet containing polyethyleneimine ( PEI) based nanoparticles (prepared by incubating PEI with green fluorescent protein (GFP) plasmid DNA) containing an active agent such as antibacterial, antiviral agent, blood coagulation protein, gene etc. drug delivery to sites of vascular injury
11/20/2008US20080286363 (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one maleate; 3-[(Cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide (glycopyrrolate), and a glucocorticosteroids
11/20/2008US20080286362 mixture of non-aggregated isooctyltrimethoxysilane modified silica nanoparticle and solid bulk material in the form of a powder, containing a drug; free flowing; use in inhalation device
11/20/2008US20080286361 deliverying a therapeutic agent (DNA, CFTR genes, peptide, antibody etc. ) contained in targeting particles (e.g. magnetite) to a cell using an electromagnet to apply a magnetic force so as to tend to move particles towards magnet and at the same time moving the magnet
11/20/2008US20080286359 sodium risedronate, disodium ethylenediaminetetraacetic acid, citric acid or sodium hexametaphosphate as chelating agent for immediate release of risedronate and the chelating agent to the small intestine of the mammal and absorption of risedronate when administered with or without food and beverages
11/20/2008US20080286357 Multi-functional particulate delivery system for pharmacologically active ingredients
11/20/2008US20080286356 Pharmaceutical compositions containing terbinafin and use thereof
11/20/2008US20080286354 administering a bile acid e.g ursodiol, ursodiol bicarbonate and ursodiol sulfate, a fibrate e.g. bezafibrate, fenofibrate, gemfibrozil, ciprofibrate and derivatives of 2-phenoxy-2-methylpropanoic acid, and a statin e.g. simvastatin, fluvastatin, pravastatin, atorvastatin to treat chronic hepatitis
11/20/2008US20080286353 Cationic liposomes containing immune response generating moieties
11/20/2008US20080286352 Liposome Compositions
11/20/2008US20080286351 Pegylated Cardiolipin Analogs, Methods of Synthesis, and Uses Thereof
11/20/2008US20080286349 Systems, devices, and methods for passive transdermal delivery of active agents to a biological interface
11/20/2008US20080286341 Oral drug delivery; Arginine, Aspargine, Glutamic acid, Glutamine buffer coating buffer; nicotine, cyclodextrin complex core; polyacrylate cation exchanger; lozenges, tablets; reduce the urge to smoke
11/20/2008US20080286340 Oral drug delivery; Arginine, Aspargine, Glutamic acid, Glutamine buffer coating buffer; nicotine, cyclodextrin complex core; polyacrylate cation exchanger; lozenges, tablets; reduce the urge to smoke
11/20/2008US20080286339 Using multi-segment device to deliver selective androgen and estrogen receptor modulators to women in order to relieve symptoms associated with menopause
11/20/2008US20080286338 Drug delivery system with scleral lens
11/20/2008US20080286337 Method of treating a disease in an eye using a scleral lens
11/20/2008US20080286334 Poly lactic co-glycolic acid copolymer biodegradable polymer matrix; eye implant infused with ace-inhibitors, endogenous cytokines, agents that influence basement membrane, agents that influence the growth of endothelial cells, adrenergic agonists or blockers; uveitis, macular edema, macular degeneration
11/20/2008US20080286327 Thombolysis and chronic anticoagulation therapy
11/20/2008US20080286325 Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
11/20/2008US20080286322 Methods and devices for the sustained release of multiple drugs
11/20/2008US20080286321 Polymer No Donor Predrug Nanofiber Coating for Medical Devices and Therapy
11/20/2008US20080286320 Absorbent article comprising a lotion composition for reducing adherence of feces or menses to the skin
11/20/2008US20080286316 Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods
11/20/2008US20080286291 Betulinol Derivatives as Anti-Hiv Agents
11/20/2008US20080286290 Anti-Cd14 Antibody Fusion Protein
11/20/2008US20080286287 Methods and Agents for Modulating Cellular Activity
11/20/2008US20080286284 Compositions of PSMA antibodies
11/20/2008US20080286282 Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor
11/20/2008US20080286280 Stable Lyophilized Pharmaceutical Preparations of Monoclonal or polyclonal antibodies
11/20/2008US20080286279 Treatment of Severe Community-Acquired Pneumonia by Administration of Tissue Factor Pathway Inhibitor (Tfpi)
11/20/2008US20080286265 Substituted phenoxy n-alkylated thiazolidinediones as estrogen related receptor-alpha modulators
11/20/2008US20080286264 Modulation of Muc1 Activity
11/20/2008US20080286261 Methods of modulating hair growth
11/20/2008US20080286260 Diagnostic and Therapeutics for Diseases Associated with Peroxisome Proliferative Activated Receptor Alpha (Ppara)
11/20/2008US20080286258 Bifeprunox mesylate maintenance dose compositions and methods for using the same
11/20/2008US20080286252 Processing of Natural Polysaccharides by Selected Non-Pathogenic Microorganisms and Methods of Making and Using the Same
11/20/2008US20080286248 Hiv Vif Mutants
11/20/2008US20080286239 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
11/20/2008US20080286234 Method for treating demyelinating diseases
11/20/2008US20080286232 Methods for treating sarcoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6 dioxo(3-piperidyl))-isoindoline-1,3-dione
11/20/2008US20080286231 Novel inhibitors of glutaminyl cyclase
11/20/2008US20080286230 Compounds and pharmaceutical compositions for the treatment of viral infections
11/20/2008US20080286224 Use of a Lotion Composition on an Absorbent Article for Reducing Adherence of Feces or Menses to the Skin
11/20/2008US20080286223 Compositions Having a High Antiviral and Antibacterial Efficacy
11/20/2008US20080286222 Oily solid cosmetics
11/20/2008US20080286221 Comprise ethyl methacrylate, at least one alpha , beta -ethylenically unsaturated amide group-containing compound and at least one monoethylenically unsaturated carboxylic acid; cosmetic and pharmaceutical use
11/20/2008US20080286213 Comprising morusin, Cortex Mori (White Mulberry root-bark), for use in manufacturing antibacterial medicaments or oral care products; treatment of caries and periodontal disease
11/20/2008US20080286209 Comprising isoprenoid-based compounds (e.g., farnesol and/or farnesol analogues or derivatives) or dehydroisoprenoid-based compounds, for use in treating (e.g., suppressing) alcohol withdrawal syndrome and associated neurological symptoms (e.g., depression, tremor, anxiety)
11/20/2008US20080286205 Method for Treating Prostate Diseases Based on Local Delivery of Active Substances
11/20/2008US20080286204 Including cystic fibrosis transmembrane conductance regulator ("CFTR"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis
11/20/2008DE102007022790A1 Axomadol zur Schmerzbehandlung bei Arthrose Axomadol for pain management in osteoarthritis
11/20/2008DE102007022565A1 Heterocyclische Indazolderivate Heterocyclic indazole derivatives
11/20/2008DE102005059420B4 Verwendung einer Hypromellose enthaltende zu einer Buccaltablette gepressten Haftpaste zur Behandlung lokaler Erkrankungen der Mundschleimhaut Using a Hypromellose containing compressed to a buccal adhesive paste for treatment of local diseases of the oral mucosa
11/20/2008CA2756796A1 Novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives
11/20/2008CA2705612A1 Radiation protection and treatment for exposure to gamma-radiation
11/20/2008CA2687715A1 Screening assay to identify correctors of protein trafficking defects
11/20/2008CA2687410A1 Uses of north american ginseng fractions for treating leukemia
11/20/2008CA2687385A1 New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use
11/20/2008CA2687380A1 New pharmaceutical compositions comprising diiodothyronine and their therapeutic use
11/20/2008CA2687303A1 ((phenyl)imidazolyl)methylheteroaryl compounds
11/20/2008CA2687254A1 Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
11/20/2008CA2687204A1 A synergistic pharmaceutical combination for the treatment of cancer
11/20/2008CA2687162A1 Heterocyclic indazole derivatives
11/20/2008CA2687079A1 Methods of treatment of skin ulcers
11/20/2008CA2687007A1 Polymerase inhibitors and the use thereof for the treatment of tumors
11/20/2008CA2686997A1 Quaternary alkyl ammonium bacterial efflux pump inhibitors and therapeutic uses thereof
11/20/2008CA2686931A1 Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
11/20/2008CA2686909A1 Pyrazolone derivatives as pde4 inhibitors
11/20/2008CA2686908A1 Rna antagonist compounds for the modulation of her3
11/20/2008CA2686906A1 Sgc stimulators, sgc activators and combinations for the treatment of urological disorders
11/20/2008CA2686903A1 Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors
11/20/2008CA2686885A1 Composition for maintaining androgen and androgen-like uptake potential by cells
11/20/2008CA2686848A1 Methods of treatment using intravenous formulations comprising temozolomide
11/20/2008CA2686838A1 Modulators of cftr
11/20/2008CA2686768A1 Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
11/20/2008CA2686766A1 (s,r)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent
11/20/2008CA2686765A1 Aqueous pharmaceutical composition
11/20/2008CA2686754A1 Hetarylanilines as modulators for amyloid beta